Market revenue in 2023 | USD 4.8 million |
Market revenue in 2030 | USD 6.2 million |
Growth rate | 3.8% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.42% in 2023. Horizon Databook has segmented the Saudi Arabia cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
In 2023, Saudi Arabia accounted for 27.7% of the MEA market. This growth can be attributed to several factors, including an increase in the number of approved gene therapy products & biological therapies and growing public awareness of the advantages of effective biopharmaceutical solutions.
For example, in January 2024, Vertex Pharmaceuticals announced the clearance of CASGEVY (exagamglogene autotemcel [exa-cel]), the first CRISPR/Cas9 gene-edited medicine for treating Sickle Cell Disease (SCD) and transfusion-dependent beta-thalassemia in patients aged 12 and above.
CASGEVY is the first medication assessed under the SFDA's breakthrough medicines program after the company was given approval by the Saudi SFDA. It is a form of genome editing technology called CRISPR/Cas9-based cellbased gene therapy. CRISPR/Cas9 technology is used to modify the genomes of hematopoietic stem cells in patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account